Taxane‐platinum‐fluoropyrimidine combinations probably leads to lower progression‐free survival compared with taxane‐platinum (without fluoropyrimidine) (moderate certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment‐related death compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes treatment discontinuation due to toxicity compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
S‐1 showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (high certainty).
It is very uncertain whether S‐1 changes tumour response compared with 5‐FU‐containing regimens (very low certainty).
S‐1 showed no clear difference in progression‐free survival compared with 5‐FU‐containing regimens (low certainty).
S‐1 showed no clear difference in time‐to treatment failure compared with 5‐FU‐containing regimens (low certainty).
S‐1 showed no clear difference in treatment‐related deaths compared with 5‐FU‐containing regimens (moderate certainty).
S‐1 showed no clear difference in treatment discontinuation due to toxicity compared with 5‐FU‐containing regimens (high certainty).
5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).
5‐FU/cisplatin/anthracycline combinations may leads to higher tumour response compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
5‐FU/cisplatin/anthracycline combinations may leads to lower time to progression compared with 5‐FU/cisplatin combinations (without anthracyclines) (low certainty).
The intervention showed no clear difference in mortality (calculated instead of overall survival) (moderate certainty).
The intervention probably leads to lower relapse, progression or death (calculated instead of PFS)… (moderate certainty).
The intervention showed no clear difference in infection‐ related mortality (low certainty).
The intervention showed no clear difference in second cancer‐ related mortality (low certainty).
The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).
The review found no eligible studies for this question.
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
The intervention probably leads to lower relapse, progression or death (calculated instead of PFS) (moderate certainty).